Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

HDM1005

Stage Phase 3Stale

Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co

Route injection

Class GLP-1/GIP

Mechanism GLP-1 and GIP dual agonist

Sources

registry, as of 2025-12-12Stale

https://clinicaltrials.gov/study/NCT07279194

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 825. Conditions Obesity & Overweight. This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a rati

ClinicalTrials.gov NCT07279194 protocol and results modules

registry, as of 2026-08-31Stale

https://clinicaltrials.gov/study/NCT07794397

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 200. Conditions Obstructive Sleep Apnea (OSA) and Obesity. This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity receiving positive airway pressure (PAP) therapy. Eligible participants will be screened and random

ClinicalTrials.gov NCT07794397 protocol and results modules

registry, as of 2026-08-26Stale

https://clinicaltrials.gov/study/NCT07787260

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 200. Conditions Obstructive Sleep Apnea (OSA) and Obesity. This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity not receiving positive airway pressure (PAP) therapy. Eligible participants will be screened and ra

ClinicalTrials.gov NCT07787260 protocol and results modules

registry, as of 2025-09-30Stale

https://clinicaltrials.gov/study/NCT06886126

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus. Overall status RECRUITING. Phases PHASE2. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 240. Conditions Obesity. It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.

ClinicalTrials.gov NCT06886126 protocol and results modules

registry, as of 2026-10-01Stale

https://clinicaltrials.gov/study/NCT07828197

A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 135. Conditions Overweight and/or Obesity; Healthy Participants. The purpose of this study is to evaluate the relative bioavailability of a single subcutaneous injection of HDM1005 solution at different injection sites (upper arm and thigh)by using the abdomen subcutaneous injection as a control.

ClinicalTrials.gov NCT07828197 protocol and results modules

registry, as of 2026-08-24Stale

https://clinicaltrials.gov/study/NCT06637020

Phase Ib Clinical Study of HDM1005 Injection. Overall status COMPLETED. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 80. Conditions Overweight and Obesity. This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HDM1005 injection in overweight or obese subj

ClinicalTrials.gov NCT06637020 protocol and results modules

registry, as of 2025-12-16Stale

https://clinicaltrials.gov/study/NCT06640647

Phase Ia Clinical Study of HDM1005 Injection. Overall status COMPLETED. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 65. Conditions Obesity and Overweight. This is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase Ia clinical study. It is aimed to evaluate the safety, tolerability, PK and PD characteristics of HDM1005 injection in healthy adult subjects.

ClinicalTrials.gov NCT06640647 protocol and results modules

registry, as of 2026-03-30Stale

https://clinicaltrials.gov/study/NCT07502001

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 42. Conditions Overweight; Obesity. The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.

ClinicalTrials.gov NCT07502001 protocol and results modules

publication, as of 2026-07-16Stale

https://pubmed.ncbi.nlm.nih.gov/42125916/

Dual Agonist by Molecular Dynamics Evolution. HDM1005 ( poterepatide ), a novel highly potent GLP-1/GIP dual agonist, was engineered via computational alanine scanning and rational acylation design. Nonacylated HDM1005 ( P001 ) showed stable receptor binding and higher affinity than nonacylated

PMID 42125916

Studies

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

Registry NCT07279194

Phase Phase 3

Status Recruiting

Enrollment 825

Start 2025-10-14

Primary completion 2026-09-20

Study completion 2026-12-13

Catalyst Primary completion. 2026-09-20. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HDM1005 Cohort 1

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity & Overweight

HDM1005 Cohort 2

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity & Overweight

Placebo

Regimen once weekly

Weeks 52

Population Obesity & Overweight

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Ap

Registry NCT07794397

Phase Phase 3

Status Not yet recruiting

Enrollment 200

HDM1005

Regimen once weekly

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea (OSA) and Obesity

Placebo

Regimen once weekly

Weeks 52

Population Obstructive Sleep Apnea (OSA) and Obesity

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Ap

Registry NCT07787260

Phase Phase 3

Status Not yet recruiting

Enrollment 200

HDM1005

Regimen once weekly

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea (OSA) and Obesity

Placebo

Regimen once weekly

Weeks 52

Population Obstructive Sleep Apnea (OSA) and Obesity

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

Registry NCT06886126

Phase Phase 2

Status Recruiting

Enrollment 240

Start 2025-02-07

Primary completion 2025-09-23

Study completion 2025-11-30

Catalyst Primary completion. 2025-09-23. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HDM1005 dose cohort 1 QW

Comparator placebo

Population Obesity

HDM1005 dose cohort 2 QW

Comparator placebo

Population Obesity

HDM1005 dose cohort 3 QW

Comparator placebo

Population Obesity

HDM1005 dose cohort 4 QW

Comparator placebo

Population Obesity

placebo QW

Population Obesity

A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites

Registry NCT07828197

Phase Phase 1

Status Active, not recruiting

Enrollment 135

Start 2026-09-03

Cohort 1 (Abdomen)

Population Overweight and/or Obesity; Healthy Participants

Cohort 2 (Upper arm)

Population Overweight and/or Obesity; Healthy Participants

Cohort 3 (Thigh)

Population Overweight and/or Obesity; Healthy Participants

Phase Ib Clinical Study of HDM1005 Injection

Registry NCT06637020

Phase Phase 1

Status Completed

Enrollment 80

Start 2024-06-21

Primary completion 2025-03-28

Study completion 2025-06-24

Catalyst Primary completion. 2025-03-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HDM1005 injection dose level 1(Part 1)

Regimen once weekly

Weeks 4

Population Overweight and Obesity

HDM1005 injection dose level 2 (Part 1)

Regimen once weekly

Weeks 4

Population Overweight and Obesity

HDM1005 injection dose level 3 (Part 1)

Regimen once weekly

Weeks 4

Population Overweight and Obesity

HDM1005 injection dose level 4 (Part 1)

Regimen once weekly

Weeks 4

Population Overweight and Obesity

Experimental: HDM1005 injection one dose level with stepwise titration from a lower dose (Part 2)

Regimen once weekly

Weeks 4

Population Overweight and Obesity

Phase Ia Clinical Study of HDM1005 Injection

Registry NCT06640647

Phase Phase 1

Status Completed

Enrollment 65

Start 2024-03-19

Primary completion 2024-08-06

Study completion 2024-09-26

HDM1005 injection dose level 1

Population Obesity and Overweight

HDM1005 injection dose level 2

Population Obesity and Overweight

HDM1005 injection dose level 3

Population Obesity and Overweight

HDM1005 injection dose level 4

Population Obesity and Overweight

HDM1005 injection dose level 5

Population Obesity and Overweight

HDM1005 injection dose level 6

Population Obesity and Overweight

HDM1005 injection dose level 7

Population Obesity and Overweight

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

Registry NCT07502001

Phase Phase 1

Status Not yet recruiting

Enrollment 42

Start 2026-04-08

Primary completion 2026-12-01

Study completion 2027-06-02

Catalyst Primary completion. 2026-12-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Treatment group

Population Overweight; Obesity